Platelet Transfusion and Thrombosis: More Questions than Answers

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 2, 2015, Pages 118-124

  Schmidt, Amy E ^a   Refaai, Majed A ^a   Blumberg, Neil ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

microparticles; platelets; thrombosis; transfusion

Indexed keywords

APOPTOSIS; ARTICLE; BLOOD CLOT RETRACTION; BLOOD CLOTTING; BLOOD GROUP ABO SYSTEM; CARDIOVASCULAR MORTALITY; CORONARY STENT; CRITICALLY ILL PATIENT; DRUG ELUTING STENT; GAMMA IRRADIATION; GENETIC ASSOCIATION; HALF LIFE TIME; HEPATITIS B VIRUS; HEPATITIS C VIRUS; IMMUNOMODULATION; PRIORITY JOURNAL; SENESCENCE; STORAGE TEMPERATURE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOSIS; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD; BLOODBORNE BACTERIUM; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION; VIRUS INFECTION;

ACUTE LUNG INJURY; BLOOD-BORNE PATHOGENS; HUMANS; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; VIRUS DISEASES;

EID: 84959093598     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-00000077     Document Type: Article

References (85)

1. Khorana A. A., Francis C. W., Blumberg N., Culakova E., Refaai M. A., Lyman G. H. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med: 2008; 168 21 2377 2381
2. de Boer M. T., Christensen M. C., Asmussen M., et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg: 2008; 106 1 32 44
3. Cornet A. D., Klein L. J., Groeneveld A. B. Coronary stent occlusion after platelet transfusion: a case series. J Invasive Cardiol: 2007; 19 10 E297 E299
4. Shin H. S., Kang T. S. A case of late stent thrombosis following platelet transfusion in a patient with aplastic anemia. Korean Circ J: 2012; 42 1 54 57
5. Goel R., Ness P. M., Takemoto C. M., Krishnamurti L., King K. E., Tobian A. A. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood: 2015; 125 9 1470 1476
6. Solomon C., Traintinger S., Ziegler B., et al. Platelet function following trauma. A multiple electrode aggregometry study. Thromb Haemost: 2011; 106 2 322 330
7. Kutcher M. E., Redick B. J., McCreery R. C., et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg: 2012; 73 1 13 19
8. Briggs A., Gates J. D., Kaufman R. M., Calahan C., Gormley W. B., Havens J. M. Platelet dysfunction and platelet transfusion in traumatic brain injury. J Surg Res: 2015; 193 2 802 806
9. Windelov N. A., Sorensen A. M., Perner A., et al. Platelet aggregation following trauma: a prospective study. Blood Coagul Fibrinolysis: 2014; 25 1 67 73
10. Cap A., Hunt B. J. The pathogenesis of traumatic coagulopathy. Anaesthesia: 2015; 70 01 96 101, e32-e34
11. Etulain J., Negrotto S., Carestia A., et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost: 2012; 107 1 99 110
12. Sinauridze E. I., Kireev D. A., Popenko N. Y., et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost: 2007; 97 3 425 434
13. Sims P. J., Wiedmer T., Esmon C. T., Weiss H. J., Shattil S. J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem: 1989; 264 29 17049 17057
14. Wiedmer T., Shattil S. J., Cunningham M., Sims P. J. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry: 1990; 29 3 623 632
15. Italiano J. E. Jr, Mairuhu A. T., Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol: 2010; 17 6 578 584
16. Zwaal R. F., Comfurius P., Bevers E. M. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta: 1992; 1180 1 1 8
17. Goubran H. A., Burnouf T., Stakiw J., Seghatchian J. Platelet microparticle: a sensitive physiological fine tuning balancing factor in health and disease. Transfus Apheresis Sci: 2015; 52 1 12 18
18. Miyazaki Y., Nomura S., Miyake T., et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood: 1996; 88 9 3456 3464
19. Holme P. A., Orvim U., Hamers M. J., et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol: 1997; 17 4 646 653
20. Chow T. W., Hellums J. D., Thiagarajan P. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. J Lab Clin Med: 2000; 135 1 66 72
21. Flaumenhaft R., Dilks J. R., Richardson J., et al. Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles. Blood: 2009; 113 5 1112 1121
22. Gyulkhandanyan A. V., Mutlu A., Freedman J., Leytin V. Markers of platelet apoptosis: methodology and applications. J Thromb Thrombolysis: 2012; 33 4 397 411
23. Bassé F., Gaffet P., Bienvenüe A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: are vesicles shed by filopod fragmentation? Biochim Biophys Acta: 1994; 1190 2 217 224
24. Willerson J. T., Golino P., Eidt J., Campbell W. B., Buja L. M. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation: 1989; 80 1 198 205
25. Lee Y. J., Jy W., Horstman L. L., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res: 1993; 72 4 295 304
26. Sims P. J., Wiedmer T. Repolarization of the membrane potential of blood platelets after complement damage: evidence for a Ca++ -dependent exocytotic elimination of C5b-9 pores. Blood: 1986; 68 2 556 561
27. Lim M. Y., Ataga K. I., Key N. S. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol: 2013; 20 5 472 477
28. Lopes-Virella M. F., Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes: 1992; 41 02 86 91
29. Blumberg N., Spinelli S. L., Francis C. W., Taubman M. B., Phipps R. P. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res: 2009; 45 2-3 251 260
30. Nomura S., Okamae F., Abe M., et al. Platelets expressing P-selectin and platelet-derived microparticles in stored platelet concentrates bind to PSGL-1 on filtrated leukocytes. Clin Appl Thromb Hemost: 2000; 6 4 213 221
31. Prasad K. S., Andre P., Yan Y., Phillips D. R. The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol: 2003; 10 5 356 361
32. Siljander P., Carpen O., Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood: 1996; 87 11 4651 4663
33. Matijevic N., Wang Y. W., Kostousov V., Wade C. E., Vijayan K. V., Holcomb J. B. Decline in platelet microparticles contributes to reduced hemostatic potential of stored plasma. Thromb Res: 2011; 128 1 35 41
34. Muellner S. K., Haut E. R., Streiff M. B., Holcomb J. B., Cotton B. A. ABO blood group as a potential risk factor for venous thromboembolism in acutely injured patients. Thromb Haemost: 2011; 105 1 5 13
35. Windelov N. A., Johansson P. I., Sorensen A. M., et al. Low level of procoagulant platelet microparticles is associated with impaired coagulation and transfusion requirements in trauma patients. J Trauma Acute Care Surg: 2014; 77 5 692 700
36. Matijevic N., Wang Y. W., Wade C. E., et al. PROMMTT Study Group. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res: 2014; 134 3 652 658
37. Lannan K. L., Phipps R. P., White R. J. Thrombosis, platelets, microparticles and PAH: more than a clot. Drug Discov Today: 2014; 19 8 1230 1235
38. Damås J. K., Otterdal K., Yndestad A., et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation: 2004; 110 8 999 1005
39. Diehl P., Aleker M., Helbing T., et al. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. Interact Cardiovasc Thorac Surg: 2010; 11 2 133 137
40. Nadaud S., Poirier O., Girerd B., et al. Small platelet microparticle levels are increased in pulmonary arterial hypertension. Eur J Clin Invest: 2013; 43 1 64 71
41. Bakouboula B., Morel O., Faure A., et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med: 2008; 177 5 536 543
42. Burnouf T., Goubran H. A., Chou M. L., Devos D., Radosevic M. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Rev: 2014; 28 4 155 166
43. Morelli V. M., De Visser M. C., Vos H. L., Bertina R. M., Rosendaal F. R. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost: 2005; 3 1 183 185
44. Morelli V. M., de Visser M. C., van Tilburg N. H., et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost: 2007; 97 4 534 541
45. Franchini M., Lippi G. Relative risks of thrombosis and bleeding in different ABO blood groups. Semin Thromb Hemost: 2016; 42 2 112 117
46. Talbot S., Wakley E. J., Ryrie D., Langman M. J. ABO blood-groups and venous thromboembolic disease. Lancet: 1970; 1 7659 1257 1259
47. Tirado I., Mateo J., Soria J. M., et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost: 2005; 93 3 468 474
48. Gill J. C., Endres-Brooks J., Bauer P. J., Marks W. J. Jr, Montgomery R. R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood: 1987; 69 6 1691 1695
49. Gallinaro L., Cattini M. G., Sztukowska M., et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood: 2008; 111 7 3540 3545
50. Nossent A. Y., VAN Marion V., VAN Tilburg N. H., et al. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost: 2006; 4 12 2556 2562
51. O'Donnell J., Boulton F. E., Manning R. A., Laffan M. A. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol: 2002; 22 2 335 341
52. Wiggins K. L., Smith N. L., Glazer N. L., et al. ABO genotype and risk of thrombotic events and hemorrhagic stroke. J Thromb Haemost: 2009; 7 2 263 269
53. Nydegger U. E., Wuillemin W. A., Julmy F., Meyer B. J., Carrel T. P. Association of ABO histo-blood group B allele with myocardial infarction. Eur J Immunogenet: 2003; 30 3 201 206
54. von Beckerath N., Koch W., Mehilli J., et al. ABO locus O1 allele and risk of myocardial infarction. Blood Coagul Fibrinolysis: 2004; 15 1 61 67
55. Reilly M. P., Li M., He J., et al. Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet: 2011; 377 9763 383 392
56. Barbalic M., Dupuis J., Dehghan A., et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet: 2010; 19 9 1863 1872
57. Qi L., Cornelis M. C., Kraft P., et al. Genetic variants in ABO blood group region, plasma soluble E-selectin levels and risk of type 2 diabetes. Hum Mol Genet: 2010; 19 9 1856 1862
58. Zhou S., Welsby I. Is ABO blood group truly a risk factor for thrombosis and adverse outcomes? World J Cardiol: 2014; 6 9 985 992
59. Tan K. T., Tayebjee M. H., Lim H. S., Lip G. Y. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med: 2005; 22 12 1657 1662
60. Vidal C., Spaulding C., Picard F., et al. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost: 2001; 86 3 784 790
61. Suades R., Padró T., Vilahur G., Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost: 2012; 108 6 1208 1219
62. Refaai M. A., Carter J., Henrichs K. F., et al. Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B. Transfusion: 2013; 53 2 382 393
63. Refaai M. A., Fialkow L. B., Heal J. M., et al. An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang: 2011; 101 1 55 60
64. Salunkhe V., van der Meer P. F., de Korte D., Seghatchian J., Gutiérrez L. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Apheresis Sci: 2015; 52 1 19 34
65. McCullough J., Vesole D. H., Benjamin R. J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood: 2004; 104 5 1534 1541
66. Kerkhoffs J. L., van Putten W. L., Novotny V. M., et al. Dutch - Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol: 2010; 150 2 209 217
67. Lozano M., Knutson F., Tardivel R., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol: 2011; 153 3 393 401
68. Perez-Pujol S., Tonda R., Lozano M., et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion: 2005; 45 6 911 919
69. Zeddies S., De Cuyper I. M., van der Meer P. F., et al. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion: 2014; 54 9 2292 2300
70. Seghatchian J., Tolksdorf F. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update. Transfus Apheresis Sci: 2012; 46 2 221 229
71. Zhu M., Xu W., Wang B. L., Su H. Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients. Transfus Med Hemother: 2014; 41 3 189 196
72. Seghatchian J., Krailadsiri P. Platelet storage lesion and apoptosis: are they related? Transfus Apheresis Sci: 2001; 24 1 103 105
73. Murphy W. G., Coakley P. Testing platelet components for bacterial contamination. Transfus Apheresis Sci: 2011; 45 1 69 74
74. Reddoch K. M., Pidcoke H. F., Montgomery R. K., et al. Hemostatic function of apheresis platelets stored at 4°C and 22°C. Shock: 2014; 41 01 54 61
75. Ayukawa O., Nakamura K., Kariyazono H., et al. Enhanced platelet responsiveness due to chilling and its relation to CD40 ligand level and platelet-leukocyte aggregate formation. Blood Coagul Fibrinolysis: 2009; 20 3 176 184
76. Slichter S. J., Harker L. A. Preparation and storage of platelet concentrates. Transfusion: 1976; 16 1 8 12
77. Valeri C. R. Circulation and hemostatic effectiveness of platelets stored at 4 C or 22 C: studies in aspirin-treated normal volunteers. Transfusion: 1976; 16 1 20 23
78. Becker G. A., Tuccelli M., Kunicki T., Chalos M. K., Aster R. H. Studies of platelet concentrates stored at 22 C nad 4 C. Transfusion: 1973; 13 2 61 68
79. Murphy S., Gardner F. H. Effect of storage temperature on maintenance of platelet viability--deleterious effect of refrigerated storage. N Engl J Med: 1969; 280 20 1094 1098
80. Khuri S. F., Healey N., MacGregor H., et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg: 1999; 117 1 172 183, discussion 183-184
81. Dumont L. J., Cancelas J. A., Dumont D. F., et al. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion: 2013; 53 1 128 137
82. Johnson L., Reid S., Tan S., Vidovic D., Marks D. C. PAS-G supports platelet reconstitution after cryopreservation in the absence of plasma. Transfusion: 2013; 53 10 2268 2277
83. Johnson L. N., Winter K. M., Reid S., Hartkopf-Theis T., Marks D. C. Cryopreservation of buffy-coat-derived platelet concentrates in dimethyl sulfoxide and platelet additive solution. Cryobiology: 2011; 62 2 100 106
84. Valeri C. R., Macgregor H., Ragno G. Correlation between in vitro aggregation and thromboxane A2 production in fresh, liquid-preserved, and cryopreserved human platelets: effect of agonists, pH, and plasma and saline resuspension. Transfusion: 2005; 45 4 596 603
85. Johnson L., Coorey C. P., Marks D. C. The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles. Transfusion: 2014; 54 8 1917 1926